Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

» AVNR's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

AVNR Guru Trades in Q2 2014

Steven Cohen 201,800 sh (unchged)
» More
Q3 2014

AVNR Guru Trades in Q3 2014

Chuck Royce 1,289,100 sh (New)
Paul Tudor Jones 127,470 sh (New)
Jim Simons 58,014 sh (New)
Louis Moore Bacon 100,000 sh (New)
Leon Cooperman 100,000 sh (New)
Steven Cohen 498,500 sh (+147.03%)
» More
Q4 2014

AVNR Guru Trades in Q4 2014

Mario Gabelli 493,524 sh (New)
Jim Simons 884,514 sh (+1424.66%)
Louis Moore Bacon 150,000 sh (+50.00%)
Louis Moore Bacon 150,000 sh (unchged)
Steven Cohen Sold Out
Leon Cooperman Sold Out
Chuck Royce 405,100 sh (-68.57%)
Paul Tudor Jones 22,895 sh (-82.04%)
» More
Q1 2015

AVNR Guru Trades in Q1 2015

Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVNR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Traded in other countries:AV2B.Germany,

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $115.0
EPS (TTM) $ -0.31
Short Percentage of Float8.94%
52-Week Range $3.02 - 17.05
Shares Outstanding (Mil)193.76

Analyst Estimate

Sep15 Sep16
Revenue (Mil $) 23 100
EPS ($) -4.56 -3.55
EPS w/o NRI ($) -4.56 -3.55
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for AVNR


Articles On GuruFocus.com
Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
A Look at Leon Cooperman's Most Performing Recent Buys Jan 30 2015 
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 

More From Other Websites
Avanir Pharmaceuticals to Present Data on ONZETRA™ Xsail™ at American Headache Society (AHS)... Jun 09 2016
NUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other... Jun 08 2016
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA™ Xsail™ for the Acute... May 16 2016
Avanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA™ Xsail™ at American Academy of... Apr 15 2016
Avanir Pharmaceuticals Announces FDA Approval of ONZETRA™ Xsail™ (AVP-825) for the Acute... Jan 28 2016
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as President and Chief Executive... Jan 20 2016
Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients... Dec 10 2015
Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar... Dec 01 2015
Concert Pharmaceuticals Achieves $2 Million Milestone from Avanir Pharmaceuticals for Phase 3... Nov 16 2015
Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients... Nov 16 2015
Avanir reports 4Q loss Jan 05 2015
Japanese firm Otsuka to buy Avanir Pharmaceuticals for $3.5 billion Dec 02 2014
Energy companies lead an advance in US stocks Dec 02 2014
Stocks head higher, bouncing back from day before Dec 02 2014
Japanese firm to buy Avanir Pharmaceuticals for $3.5 billion Dec 02 2014
Japan's Otsuka to buy Avanir for $3.5 bln ahead of patent cliff Dec 02 2014
Otsuka Pharmaceutical Plans $3.5 Billion Avanir Takeover Dec 02 2014
Are Avanir Shareholders Getting Enough in the Buyout? Dec 02 2014
Otsuka to buy US drugmaker Avanir for $3.5B Dec 02 2014
Avanir to be bought by Japan's Otsuka Pharmaceutical for $3.5 bln Dec 02 2014
FDA rejects Avanir's migraine drug-device Nov 26 2014
Avanir Pharma prices $200M stock offering Sep 24 2014
Is Avanir Pharma Fully Valued After Monday’s Rally? Sep 16 2014
US STOCKS-Nasdaq slumps to worst day since July; S&P 500 dips Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)